NMD Pharma gets FDA orphan drug designation

The special status in the US comes with certain advantages for the Danish company and its lead candidate against neuromuscular disease myasthenia gravis.

Thomas Hold Pedersen, CEO of NMD Pharma | Photo: NMD Pharma / PR

NMD Pharma’s drug candidate, NMD670, has the potential to treat autoimmune neuromuscular disease myasthenia gravis, which has become evident after the US Food and Drug Administration (FDA) awarded the medicine the orphan drug designation, according to a company press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs